Recurrence of nonalcoholic steatohepatitis after liver transplantation

Czaja, Albert J.

doi:10.1002/lt.500030215

Cited by 33 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many patients with advanced disease are poor candidates for transplantation due to comorbid conditions such as obesity and complications of diabetes. Both recurrence of NASH in patients with previously established NASH [215][216][217][218] and de novo occurrence of NASH after transplantation for cryptogenic cirrhosis 12,16 can occur. Posttransplantation progression to cirrhosis may develop although predictive factors and treatment have not been well defined.…”

Section: Managementmentioning

confidence: 99%

Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference

2003

View full text Add to dashboard Cite

Section: Managementmentioning

confidence: 99%

Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference

2003

View full text Add to dashboard Cite

“…NAFLD can occur in the allograft liver as recurrence or as a de novo process [125][126][127][128][129][130][131][132][133][134][135][136] . The incidence of recurrent steatosis in patients transplanted for cryptogenic cirrhosis or NASH-cirrhosis ranges from 25%-100%, while NASH development is observed in 10%-37.5% of these cases without leading to early allograft failure (reviewed in [135] ).…”

Section: Nash In the Transplanted Livermentioning

confidence: 99%

Histopathology of Non-Alcoholic Fatty Liver Disease

Brunt

2009

Clinics in Liver Disease

115

View full text Add to dashboard Cite

Histological analysis of liver biopsies remains a standard against which other methods of assessment for the presence and amount of hepatic injury due to nonalcoholic fatty liver disease (NAFLD) are measured. Histological evaluation remains the sole method of distinguishing steatosis from advanced forms of NAFLD, i.e. nonalcoholic steatohepatitis (NASH) and fibrosis. Included in the lesions of NAFLD are steatosis, lobular and portal inflammation, hepatocyte injury in the forms of ballooning and apoptosis, and fibrosis. However, patterns of these lesions are as distinguishing as the lesions themselves. Liver injury in adults and children due to NAFLD may have different histological patterns. In this review, the rationale for liver biopsy, as well as the histopathological lesions, the microscopically observable patterns of injury, and the differential diagnoses of NAFLD and NASH are discussed.

show abstract

“…63 One unsettling feature of posttransplant obesity has been the finding of steatosis with inflammation and necrosis in the transplanted liver. 62 Not only have there been reports of recurrent NASH in the transplanted liver 64,65 with cirrhosis, 65 but patients with a "NASH phenotype" who undergo liver transplantation for cryptogenic cirrhosis are at 100% risk for developing steatosis within 5 years of transplantation, 66 with the attendant risks of steatohepatitis and fibrosis.…”

Section: Prevalence Of Obesity In Liver Transplant Recipientsmentioning

confidence: 99%

Long-term management of the liver transplant patient: Diabetes, hyperlipidemia, and obesity

Reuben

2001

Liver Transplantation

115

View full text Add to dashboard Cite

Key Points 1. As long-term survival improves after liver transplantation, cardiovascular complications are emerging as a major cause of late morbidity and mortality. It seems reasonable to correct the potentially reversible cardiovascular risk factors of diabetes, hyperlipidemia, and obesity, in addition to hypertension. 2. The results of liver transplantation in diabetics are acceptable in terms of morbidity, mortality, and prevalence of posttransplant diabetes, but the poor outcomes described in some series suggest that more extensive testing for macro-and microvascular disease may become necessary. T he main aim of liver transplantation, besides the immediate goal of saving life, is to return the patient to productive community living with good quality of life. It is ironic, therefore, that many of the health problems that afflict successful liver transplant recipients long term are those of community living in the developed world, including diabetes mellitus, hyperlipidemia, and obesity. These three metabolic derangements, together with hypertension, constitute adverse cardiovascular risk factors for transplant recipients. The management of diabetes in liver transplant recipients is not substantially different from its management in

show abstract

Recurrence of nonalcoholic steatohepatitis after liver transplantation

Cited by 33 publications

References 10 publications

Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference

Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference

Histopathology of Non-Alcoholic Fatty Liver Disease

Long-term management of the liver transplant patient: Diabetes, hyperlipidemia, and obesity

Contact Info

Product

Resources

About